Latest Tax Incentives News

PainChek grew recurring revenue, implemented licences and customer sites in FY2026, but its $8.94 million loss and $9.24 million operating cash outflow prompted an explicit going-concern warning from its auditor. The company is now betting that US deployments and a sharper commercial focus can convert market access into cash-generating growth.

Orbit Resources enters FY2027 with a 17.52Mt Lewis Ponds resource, a preliminary study pointing to a A$481 million pre-tax NPV and a new polymetallic sulphide discovery outside the existing resource. The gains come with familiar junior-miner constraints: a A$3.49 million annual loss, A$3.69 million in cash and further funding still required.

HITIQ has secured a $1.5 million R&D tax incentive loan facility and drawn half the available funding, providing immediate liquidity while adding interest-bearing debt. The arrangement with a related party also puts shareholder approval of proposed security in focus.

Firebrick Pharma has received a $293,000 R&D Tax Incentive payment linked to $673,000 of eligible development spending on new Nasodine products. The non-dilutive cash arrives as the company broadens its product range and pursues approvals in additional markets.

Papyrus Australia moved its banana-fibre technology into early commercialisation during FY26, signing an estimated $4.2 million TBS supply contract and delivering commercial-scale samples. But the company ended the year with $257,077 cash, negative equity and an auditor-flagged material uncertainty over its ability to continue as a going concern.

Marquee Resources has received a $549,122 R&D tax refund, adding non-dilutive cash ahead of planned drilling at its Yindi Lithium and Gold Project in Western Australia. The filing improves near-term financial flexibility but does not disclose the company’s post-refund cash balance or drilling budget.

Resonance Health has signed a 24-month alliance with London-based Image Analysis Group, making its quantitative MRI endpoints orderable across IAG’s global clinical-trial network. The opportunity is potentially significant, but remains uncontracted: two pilot studies come first, with no minimum revenue or volume commitments.

Red Metal’s Sybella project has moved closer to a development decision after heap-leach testing delivered strong rare earth extractions with low impurity levels. The company also reported a $19.17 million FY2026 profit, although most of that result came from the accounting gain tied to its Maronan Metals restructuring.

Cambium Bio has secured firm commitments for a conditional A$7.1 million placement, taking its proposed funding package to A$10.85 million for the pivotal Elate Ocular Phase 3 program. Completion depends on three inter-conditional shareholder resolutions at the company’s expected November AGM.

Great Dirt Resources has identified 24 priority manganese targets in New South Wales and confirmed rock-chip grades of up to 51.8% manganese. The exploration progress came alongside a $19.1 million FY2026 loss, largely caused by a non-cash share-based payments expense, while cash rose to $3.81 million.

Actinogen Medical has locked in full underwriting for nearly 127 million unlisted options, guaranteeing $4.77 million in fresh funding as it approaches pivotal Alzheimer’s trial results due in November.

Cycliq Group Limited reported a 20.7% revenue decline to AUD 3.79 million for FY2026, but reduced its net loss by 83% to AUD 85,897, driven by disciplined cost control and strategic platform investments.